Overall
survival (OS) in patients (pts) with platinum-sensitive relapsed serous
ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An
interim analysis. |
Jonathan A. Ledermann |
5501
|
Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. |
David Marc Gershenson |
5502
|
Multicenter
phase II study of intraperitoneal carboplatin plus intravenous
dose-dense paclitaxel in patients with suboptimally debulked epithelial
ovarian or primary peritoneal carcinoma. |
Kosei Hasegawa |
5504
|
The
MITO8 phase III international multicenter randomized study testing the
effect on survival of prolonging platinum-free interval (PFI) in
patients with ovarian cancer (OC) recurring between 6 and 12 months
after previous platinum-based chemotherapy: A collaboration of MITO,
MANGO, AGO, BGOG, ENGOT, and GCIG. |
Sandro Pignata |
5505
|
Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. |
Usha Menon |
5507
|
Baseline
quality of life (QOL) as a predictor of stopping chemotherapy early,
and of overall survival, in platinum-resistant/refractory ovarian cancer
(PRROC): The GCIG symptom benefit study (SBS). |
Felicia Roncolato |
5508
|
Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women. |
Allison W. Kurian |
5510
|
Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. |
Janos Laszlo Tanyi |
5511
|
Tumor-infiltrating
lymphocytes (TILs) and PDL1 expression in ovarian cancer (OC):
Evolution with neoadjuvant chemotherapy (NCT) and prognostic value. |
Soizick Mesnage |
5512
|
Specific
gene signatures and oligo clonal expansion of b cell repertoire with
responders of anti-PD-1 antibody, nivolumab for ovarian cancer: Novel
predictive biomarkers. |
Junzo Hamanishi |
5513
|
Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis. |
Kyle Strickland |
5514
|
A
phase II randomized, double-blind trial of a polyvalent vaccine-KLH
conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients
with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who
are in second or third complete remission. |
Paul Sabbatini |
5517
|
Prognostic
and predictive blood-based biomarkers (BMs) in patients (pts) with
advanced epithelial ovarian cancer (EOC) treated with
carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218. |
Angeles Alvarez Secord |
5521
|
Topotecan
(T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A
double-blind placebo-controlled randomized NOGGO–AGO intergroup
Trial—TRIAS. |
Jalid Sehouli |
5522
|
Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. |
Robert L. Coleman |
5523
|
Real-time
single-walled nanotube (SWNT)-based imaging system to improve tumor
detection and survival in ovarian cancer preclinical model. |
Lorenzo Ceppi |
5530
|
A
Phase II Evaluation of Temsirolimus in Combination with Carboplatin and
Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy
in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary. |
John H. Farley |
5531
|
Veliparib
monotherapy to patients with BRCA germline mutation and
platinum-resistant or partially platinum-sensitive selapse of epithelial
ovarian cancer: A phase I/II study. |
Karina Dahl Steffensen |
5532
|
Avelumab
(MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian
cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical
activity. |
Mary L. Disis |
5533
|
Evolution in epithelial ovarian cancer (OC) trials: Improving accuracy by design. |
Michelle K. Wilson |
5534
|
Safety
and efficacy of extended bevacizumab (BEV) therapy in elderly (≥70
years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in
the international ROSiA study. |
Frédéric Selle |
5535
|
Preliminary
results from the first in human study of activin-A inhibitor, STM434,
in patients with granulosa cell ovarian cancer and other advanced solid
tumors. |
David Michael Hyman |
5536
|
Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). |
Philipp Harter |
5538
|
Universal germline BRCA testing of ovarian cancer patients and implications for treatment. |
Erica Bednar |
5539
|
Refinement
of prespecified cutoff for genomic loss of heterozygosity (LOH) in
ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high
grade ovarian carcinoma (HGOC). |
Robert L. Coleman |
5540
|
Vaccination
targeting insulin-like growth factor binding protein-2 (IGFBP-2) in
advanced ovarian cancer: Safety and immunogenicity. |
John Ben Liao |
5542
|
A
phase I/II study of Enadenotucirev, a chimeric Ad11/Ad3 oncolytic group
B adenovirus, administered intraperitoneally (IP) in platinum-resistant
epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data
from phase I. |
Iain A. McNeish |
5543
|
Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study). |
Eric Hahnen |
5544
|
Glucocorticoid receptor expression and survival in ovarian cancer. |
Jennifer Taylor Veneris |
5545
|
Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer. |
Kunle Odunsi |
5546
|
Epigenetic
resensitization to platinum in recurrent, platinum-resistant ovarian
cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent
(HMA): Results of a randomized phase II study. |
Ursula A. Matulonis |
5547
|
Feasibility
of monitoring response to the PARP inhibitor rucaparib with targeted
deep sequencing of circulating tumor DNA (ctDNA) in women with
high-grade serous carcinoma on the ARIEL2 trial. |
Anna Piskorz |
5549
|
P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes. |
Victoria Mandilaras |
5550
|
Tumor
responses and preliminary survival data in a phase II trial of
ofranergene obadenovec (VB-111) combined with paclitaxel in patients
with recurrent platinum resistant ovarian cancer. |
Richard T. Penson |
5551
|
Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer. |
Sarah E Taylor |
5552
|
Serous
ovarian and primary peritoneal cancers: A comparative analysis of
clinico-pathological features, molecular subtypes and treatment outcome. |
Bo Gao |
5553
|
Endocrine therapy for ovarian cancer: A systematic review and meta-analysis of phase II studies. |
Laura Paleari |
5554
|
A
phase I study of bevacizumab in combination with niraparib in patients
with platinum-sensitive epithelial ovarian cancer: The
ENGOT-OV24/AVANOVA1 trial. |
Mansoor Raza Mirza |
5555
|
Prognostic effects of clinical and tumor (t) factors in bevacizumab (BEV)-treated patients (pts) with ovarian cancer (OC). |
Nicoletta Colombo |
5556
|
A
multicenter open-label phase II study of the efficacy and safety of
palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients
with recurrent ovarian cancer. |
Gottfried E. Konecny |
5557
|
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: The EBMT experience. |
Ugo De Giorgi |
5558
|
Where
have we gone wrong? Phase II trials (Ph2t) do not inform the results of
phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC). |
Tami Grunewald |
5559
|
Laparoscopic
versus open surgery in the treatment of apparently early stage
epithelial ovarian cancer: Case-control and case-matched study of Korean
Gynecologic Oncology Group. |
Jeong-Yeol Park |
5560
|
Randomized
trial of exercise vs. usual care on cancer biomarkers in ovarian cancer
survivors: The Women’s Activity and Lifestyle Study in Connecticut
(WALC). |
Brenda Cartmel |
5561
|
A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors. |
Erika Paige Hamilton |
5562
|
A
Markov model to evaluate cost-effectiveness of the PARP inhibitor,
olaparib, for fourth-line treatment of recurrent ovarian cancer. |
Juliet Elizabeth Wolford |
5563
|
Antitumor
activity, safety and predictive biomarker results of ENMD-2076
administered to patients (pts) with recurrent ovarian clear cell
carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium. |
Victor Rodriguez Freixinos |
5564
|
A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer. |
Sarah Patricia Blagden |
5565
|
Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy. |
Michael A. Bookman |
5566
|
IMGN853
(mirvetuximab soravtansine), a folate receptor alpha (FRĪ±)-targeting
antibody-drug conjugate (ADC): Single-agent activity in
platinum-resistant epithelial ovarian cancer (EOC) patients (pts). |
Kathleen N. Moore |
5567
|
An evaluation of the microbiota of the upper genital tract of women with benign changes and epithelial ovarian cancer. |
Wendy R. Brewster |
5568
|
A
randomized, open-label, phase II study of anti-NaPi2b antibody-drug
conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to
pegylated liposomal doxorubicin (PLD) in patients (pts) with
platinum-resistant ovarian cancer (PROC). |
Susana N. Banerjee |
5569
|
Validation of a multi-marker panel for early detection of ovarian cancer. |
Robert C. Bast |
5570
|
PISARRO:
A EUTROC phase Ib study of APR-246 in combination with carboplatin (C)
and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed
high grade serous ovarian cancer (HGSOC). |
Charlie Gourley |
5571
|
Somatic alterations in the PTEN-PI3K-AKT-mTOR pathway in a cohort of 379 ovarian cancer patients. |
Elizabeth Stover |
5572
|
Genomic
instability (GI) score post-neoadjuvant chemotherapy (NACT) to predict
overall survival (OS) in high grade ovarian cancer (HGSOC). |
Aurelie Auguste |
5573
|
The
impact of preoperative malnutrition on surgery outcome and overall
survival in ovarian or peritoneal cancer patients: A prospective study. |
Jalid Sehouli |
5574
|
Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC). |
Felicia Roncolato |
5575
|
The
primary analysis of a phase I/IIa dose finding trial of a folate
binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer
patients to prevent recurrence. |
Doreen O Jackson |
5576
|
Circulating cell-free DNA: The future of personalized medicine in ovarian cancer management. |
Rebecca Christian Arend |
5577
|
A
phase Ib/II study of cancer stemness inhibitor napabucasin (BB608)
combined with weekly paclitaxel in platinum-resistant ovarian cancer. |
Agustin A. Garcia |
5578
|
Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome. |
Victoria Mandilaras |
5579
|
Adequacy of surgical staging to predict survival in early stage ovarian cancer. |
Rachel Hope Occhiogrosso |
e17037
|
Phase
I results of GANNET53: A multicenter phase I/II trial of the Hsp90
inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women
with high-grade serous, high-grade endometrioid, or undifferentiated,
platinum-resistant epithelial ovarian, fallopian tube or primary
peritoneal cancer. |
Nicole Concin |
e17038
|
A phase I study of a p53MVA vaccine in combination with gemcitabine (GEM) in recurrent ovarian cancer (OC). |
Mihaela C. Cristea |
e17040
|
Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab. |
Christophe Boetsch |
e17042
|
Prevalence
study of germline BRCA1/2 mutation in Korean patients with high-grade
serous and/or endometrioid epithelial ovarian, Fallopian tube, or
primary peritoneal cancer. |
Eun Jin Heo |
e17043
|
ARID1A alterations in gynecological cancers as a therapeutic opportunity. |
Laura Gonzalez-Malerva |
e17044
|
In
vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor
AT13387 in high grade serous ovarian cancer patient derived xenografts. |
Panagiotis Konstantinopoulos |
e17045
|
Evaluation
of homeobox (HOX) gene expression as a prognostic biomarker of time to
recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients
treated with adjuvant carboplatin plus paclitaxel (A-C/P). |
Jai Narendra Patel |
e17046
|
Evaluating a novel oncologist-led BRCA1/2 mutation (BRCAm) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study. |
Gloria S. Huang |
e17048
|
A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors. |
Jason D. Lickliter |
e17049
|
PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study. |
Robert Allen Burger |
e17050
|
Trends
in ovarian cancer incidence and relative survival in the U.S. by
race/ethnicity and histologic subtypes: A SEER analysis 2000-2012. |
Hyo K. Park |
e17051
|
Ovarian Sertoli Leydig cell tumors: a single institution series of predominantly postmenopausal women. |
Gregory M. Gressel |
e17052
|
Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO). |
George Yaghmour |
e17053
|
Clinical
benefit and tolerability of adjuvant intraperitoneal chemotherapy in
patients who received neoadjuvant treatment for advanced ovarian cancer. |
Trishala Meghal |
e17054
|
Improved
survival of stage 4 high grade ovarian cancer patients as staged by
positron emission tomography (PETCT), who undergo chemotherapy (with a
good PETCT response) and debulking surgery as seen in a prospective
study in our cancer institution. |
Chit Cheng Yeoh |
e17055
|
Characterization of CTCs isolated from patients with recurrent ovarian cancer using an antibody-free CTC isolation device. |
Alpa Manchandia Nick |
e17056
|
PD-1, PD-L1 in BRCA1/2-mutated and non-mutated epithelial ovarian carcinomas (EOCs). |
Jasgit C. Sachdev |
e17057
|
The role of clinical and surgical factors characterizing longterm-survival in ovarian cancer. |
Hannah Woopen |
e17059
|
Genomic characterization of high-grade serous ovarian Cancer by using targeted RNA and DNAseq gene panels. |
Salvador Blanch |
e17060
|
Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation. |
Mariana de Paiva Batista |
e17061
|
Challenges in implementing a guideline for the early diagnosis of suspected ovarian cancer in Ireland. |
Marie Laffoy |
e17062
|
Effect of death receptor 6 (DR6) targeted molecular ultrasound imaging on detection of ovarian tumors at early stage. |
Animesh Barua |
e17063
|
Treatment of gynecologic cancers in HIV+ women. |
Kimberly Levinson |
e17064
|
Impact of chemotherapy on survival for low risk versus high risk early stage ovarian cancer. |
Rachel Hope Occhiogrosso |
e17066
|
IL-6 immunomodulation by antibiotics in advanced ovarian cancer patients. |
Pedro ALEJANDRO Lucero-Diaz |
e17067
|
Efficacy and safety of adjuvant intraperitoneal chemotherapy in carcinoma ovary: A prospective observational study. |
Varun Goel |
e17069
|
Association of MiR-26b mediated doxorubicin resistance signature with poor prognosis in epithelial ovarian cancer (EOC). |
Ilya Korsunsky |
e17070
|
Treatment
focused genetic testing (TFGT) for ovarian cancer (OC) patients: The
Catalan Institute of Oncology (ICO) network experience. |
Maria Pilar Barretina-Ginesta |
e17071
|
Ethnic variations in ARID1a expression in clear cell and endometrioid ovarian carcinoma. |
Tiffany Lai |
e17073
|
Accuracy
of preoperative imaging diagnosis as a possible new staging system in
advanced ovarian, tubal, and peritoneal cancer: Using data from Japan
Clinical Oncology Group study JCOG0602. |
Takashi Onda |
e17074
|
Identification
of druggable targets in high-grade epithelial ovarian cancer (EOC)
using next generation sequencing (NGS)–based molecular diagnostic. |
Jean-Louis Merlin |
e17076
|
Oncologic
outcomes of advanced gynecologic malignancies managed with the aid of
comprehensive genomic profiling (CGP) in a rural community setting. |
Luis Alexander Rojas-Espaillat |
e17077
|
Exome sequencing of ovarian cancer patients to identify variants predictive of sensitivity to chemotherapy. |
Assaad Semaan |
e17079
|
A
phase II randomized study: Outcomes after cytoreductive surgery (CRS)
with or without carboplatin hyperthermic intraperitoneal chemotherapy
(HIPEC) followed by adjuvant chemotherapy as initial treatment of
advanced stage (stage III/IV) ovarian, fallopian tube, and primary
peritoneal cancer. |
Teresa Diaz-Montes |
e17080
|
Impact of obesity on survival and recurrence of high grade serous carcinoma of the ovary. |
Carolina Ibañez |
e17081
|
Does
time-to-chemotherapy (TTC) impact the outcomes of resected ovarian
cancer? Meta-analysis of randomized and observational data. |
Diogo Bugano Diniz Gomes |
e17082
|
Evaluation of centrosome clustering protein KIFC1 as a potential prognostic biomarker in serous ovarian adenocarcinomas. |
Karuna Mittal |
e17083
|
Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target. |
Ruby Yun-Ju Huang |
e17084
|
Gene expression profiling of single circulating tumor cells in ovarian cancer: Establishment of a multi-marker gene panel. |
Tanja N. Fehm |
e17085
|
Predictive
value of ATP7b, BRCA1, BRCA2, PARP1, RAP80, HOXA9, DAXX, ERCC1,
thioredoxin-1, TSP1, and TXR1 genes in patients with epithelial ovarian
cancer (EOC) WHO received platinum-taxane first line therapy. |
Ioannis Sougklakos |
e17086
|
H2AX
and topoisomerase II expression as potential predictors of response to
treatment with pegylated liposomal doxorubicin in metastatic ovarian
cancer. |
Irene Moreno Candilejo |
e17088
|
Impact of BMI on genetic variation in ovarian cancer. |
Tara Castellano |
e17090
|
T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer. |
Yuji Ikeda |
e17091
|
Toxicity
related to first line, platinum-based chemotherapy in BRCA1-associated
epithelial ovarian cancer: Is DNA repairing impairment associated with
more adverse events? |
Agnieszka Badora-Rybicka |
e17092
|
Feasibility of an induced metabolic bioluminescence imaging technique in ovarian cancer: Results of a pilot study. |
Marco Johannes Battista |
e17093
|
Safety
and efficacy of new techniques of radiotherapy in oligometastatic
recurrence ovarian cancer (ROC) patients with BRCA 1/2 mutation. A
monoistitutional experience. |
Giuseppa Scandurra |
e17094
|
Intraperitoneal chemotherapy in pretreated ovarian cancer patients matched with patients treated with parenteral chemotherapy. |
Maria Ornella Nicoletto |
e17095
|
Cisplatin to induce cancer stem cell state in ovarian cancer. |
Caner Saygin |
e17098
|
VEGF-A and VEGF-R1 in benign and malignant ovarian tumors: Correlation with HE4 tumor marker. |
Valeria Bandovkina |
e17099
|
Metabolic
tumor burden predicts prognosis of ovarian cancer patients who receive
platinum-based adjuvant chemotherapy after cytoreductive surgery
outcome. |
Makoto Yamamoto |
e17100
|
OV21/PETROC:
A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of
intraperitoneal (IP) versus intravenous (IV) chemotherapy following
neoadjuvant chemotherapy and optimal debulking surgery in epithelial
ovarian cancer (EOC). |
Helen Mackay |
LBA5503
|
CORAIL
trial: Randomized phase III study of lurbinectedin (PM01183) versus
pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with
platinum-resistant ovarian cancer. |
Stephanie Gaillard |
TPS5597
|
SOLO3:
A randomized phase III trial of olaparib versuschemotherapy in
platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm). |
Elizabeth S. Lowe |
TPS5598
|
Phase
I/II study of niraparib plus pembrolizumab in patients with
triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162). |
Panagiotis Konstantinopoulos |
TPS5599
|
Avelumab
(MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs
pegylated liposomal doxorubicin alone in patients with
platinum-resistant/refractory ovarian cancer: The phase III JAVELIN
Ovarian 200 trial. |
Eric Pujade-Lauraine |
TPS5600
|
Phase
II evaluation of nintedanib in the treatment of bevacizumab-resistant
persistent/recurrent ovarian, fallopian tube, or primary peritoneal
carcinoma. |
Brittany Anne Davidson |
TPS5601
|
Phase
II trial of enzalutamide in patients with androgen receptor positive
(AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two
or three prior therapies. |
Rachel N. Grisham |
TPS5602
|
NiCCC
(ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120)
compared to chemotherapy in patients with recurrent clear-cell carcinoma
of the ovary or endometrium. |
Rosalind Margaret Glasspool |
TPS5603
|
TRIOC:
A randomised parallel group double-blind phase II study to assess the
activity of MVA-5T4 vaccine versus placebo in patients with relapsed
asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal
cancer. |
Agnieszka Michael |
TPS5604
|
Phase
I study of the safety and biological activity of intraperitoneal IL-12
plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in
combination with standard neoadjuvant chemotherapy in patients with
newly diagnosed ovarian cancer. |
Premal H. Thaker |
TPS5605
|
A
randomized, double-blind phase III trial of niraparib maintenance
treatment in patients with HRD+ advanced ovarian cancer after response
to front-line platinum-based chemotherapy. |
Antonio Gonzalez-Martin |
TPS5606
|
PAOLA-1:
An ENGOT/GCIG phase III trial of olaparib versus placebo combined with
bevacizumab as maintenance treatment in patients with advanced ovarian
cancer following first-line platinum-based chemotherapy plus
bevacizumab. |
Isabelle Ray-Coquard |
TPS5607
|
A
randomized, double-blind, placebo-controlled, phase II study to assess
the efficacy and safety of farletuzumab (MORAb-003) in combination with
carboplatin plus either paclitaxel or pegylated liposomal doxorubicin
(PLD) in subjects with low CA125 platinum-sensitive ovarian cancer. |
Thomas J. Herzog |
TPS5608
|
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer. |
Beverly Long |
TPS5609
|
WEE WIN: Window of opportunity study of induction Wee1 inhibition in advanced high-grade serous ovarian cancer. |
Shannon Neville Westin |
TPS5610
|
FORWARD
II: A phase Ib study to evaluate the safety, tolerability and
pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination
with bevacizumab, carboplatin or pegylated liposomal doxorubicin in
adults with folate receptor alpha (FRĪ±)-positive advanced epithelial
ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial
cancer. |
David M. O'Malley |
TPS5611
|
Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer. |
Robert Michael Wenham |
TPS5612 |
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.